Search
Hemab Therapeutics Holdings Ord Shs (Proposed)
COAGAdd to Watchlist
32.370USD
+4.650+16.77%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
1.43BMarket Cap
--P/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
5
analysts
Buy
Current Rating
41.400
Target Price
+49.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Hemab Therapeutics Holdings Ord Shs (Proposed)
COAG
5
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is the analyst rating for Hemab Therapeutics Holdings Ord Shs (Proposed)?
Based on the ratings of Hemab Therapeutics Holdings Ord Shs (Proposed)'s stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
